Jubilant Pharmova Subsidiary to Invest $300 Million in U.S. by FY28 to Double Sterile Injectable Capacity.

Jubilant HollisterStier LLC, a subsidiary of Jubilant Pharmova Ltd, will invest $300 million by FY28 to double its sterile injectable manufacturing capacity in the United States, the company announced on Friday.

Speaking to PTI, Chris Preti, CEO – CDMO Sterile Injectables, said the expansion was accelerated due to former U.S. President Donald Trump’s tariffs, which pushed the company to fast-track its plans.

As part of the initiative, Jubilant has launched a new sterile fill and finish line—the third at its Spokane manufacturing facility in Washington—developed with an investment of $132 million.

"Our overall investment is almost $300 million at our Spokane facility. This is the first of the two phases... This $132 million is phase one, which is our third line," Preti said.

The expansion aims to strengthen Jubilant’s position in the U.S. contract development and manufacturing (CDMO) market, particularly in sterile injectables.